1. AB0474 Changes in T and B Lymphocyte Subsets with Tofacitinib do not Translate from Nonclinical Species to Humans. (10th June 2014) Authors: Ball, D.J.; Kawabata, T.T.; Vogel, W.M.; Riese, R.J.; Krishnaswami, S.; Lamba, M.; Brown, M.J.; Zwillich, S.H. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 964 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690, 550). (23rd January 2014) Authors: Isaacs, J.; Nduaka, C.; Zuckerman, A.; Krishnaswami, S.; Riese, R.; Lan, S.; Hutmacher, M.; Boy, M.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0879 Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis. (15th July 2016) Authors: Ruperto, N.; Brunner, H.I.; Hazra, A.; Wang, R.; Mebus, C.; Alvey, C.; Lamba, M.; Krishnaswami, S.; Conte, U.; Wang, M.; Tzaribachev, N.; Foeldvari, I.; Horneff, G.; Kingsbury, D.; Koskova, E.; Smolewska, E.; Vehe, R.K.; Zuber, Z.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis. (10th June 2014) Authors: Alten, R.; Strand, V.; Fleischmann, R.; Koncz, T.; Zwillich, S.; Bradley, J.; Gruben, D.; Wilkinson, B.; Krishnaswami, S.; Wallenstein, G. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0253 The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT1 Signalling in Rheumatoid Arthritis. (23rd January 2014) Authors: Boyle, D. L.; Wei, N.; Singhal, A. K.; Rosengren, S.; Kaplan, I.; Soma, K.; Hodge, J.; Luo, Z.; Krishnaswami, S.; Gruben, D.; Zwillich, S. H.; Bradley, J.; Firestein, G. S. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0346 Risk Characterisation Methodology Enabling Safety Comparisons Between Tofacitinib and Tumour Necrosis Factor Inhibitors. (9th June 2015) Authors: Curtis, J.R.; Klareskog, L.; Zhang, R.; Krishnaswami, S.; Anisfeld, A.; Chen, Y.; Geier, J. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0143 Tofacitinib (CP-690, 550), an oral janus kinase inhibitor: Analyses of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatoid arthritis study population. (23rd January 2014) Authors: Kremer, J.; Zerbini, C.; Lee, E.B.; Gruben, D.; Krishnaswami, S.; Zwillich, S.H.; Koncz, T.; Bradley, J.; Mebus, C.A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib. (10th June 2014) Authors: Strand, V.; Isaacs, J.; Beal, J.; Nduaka, C.; Krishnaswami, S.; Riese, R.; Boy, M.; Menon, S. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0152 How should the primary endpoint be analysed in rheumatoid arthritis trials which mandate rescue prior to the clinical endpoint? Analysis of three phase 3 trials of tofacitinib. (23rd January 2014) Authors: Fleischmann, R.; Gruben, D.; Krishnaswami, S.; Zwillich, S.H.; Benda, B.; Mebus, C.A.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690, 550) in patients with active rheumatoid arthritis. (23rd January 2014) Authors: Fleischmann, R.M.; Krishnaswami, S.; Gruben, D.; Zwillich, S.H.; Mebus, C.; Bradley, J.D. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗